Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317381 | 0.90 | HPGD (0.44) | POLBHPGDNR1I2LMNAPYGL | |
| SCHEMBL23317635 | 0.90 | HPGD (0.39) | POLBHPGDLMNAPYGLCYP2C9 | |
| SCHEMBL23317357 | 0.90 | HPGD (0.34) | POLBHPGDNR1I2LMNAPYGL | |
| SCHEMBL23317396 | 0.87 | LMNA (0.43) | POLBHPGDNR1I2LMNAPYGL | |
| SCHEMBL23317352 | 0.87 | CYP3A4 (0.36) | POLBHPGDTSHR | |
| SCHEMBL23317287 | 0.86 | ATM (0.41) | POLBLMNACYP2C9ALDH1A1NLRP3 | |
| SCHEMBL23317600 | 0.86 | ALDH1A1 (0.38) | POLBHPGDLMNAPYGLCYP2C9 | |
| SCHEMBL23317401 | 0.83 | POLB (0.45) | POLBHPGDNR1I2LMNAPYGL | |
| SCHEMBL23317320 | 0.83 | PYGL (0.44) | POLBHPGDNR1I2LMNAPYGL | |
| SCHEMBL23317386 | 0.81 | POLB (0.43) | POLBHPGDNR1I2LMNAPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | POLB 1685/4885HPGD 1633/4885NR1I2 1922/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | POLB 1685/4885HPGD 1633/4885NR1I2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.